Other Diseases

Here are some other studies in our collection.

Study 25 – The Genes, Environment, and Development Initiative (GEDI)

Investigator:  William G. Iacono Release Date:  Available at dbGaP Abstract:  We propose using established longitudinal studies of 7300 parents and twin children to investigate how gene-environment interplay influences the development of substance abuse (SA). Our focus is on children assessed repeatedly, beginning in pre-adolescence at age 11 and then again at approximately ages 14, 17, 20, 24, and 29, making...

Read more ...

Study 26 – The Genes, Environment, and Development Initiative (GEDI)

Investigators:  E. Jane Costello, Ph.D. (Duke University), Lindon Eaves, Ph.D. (Virginia Commonwealth University) Release Date:  Available at dbGaP Abstract:  This application "A developmental model of gene-environment interplay in SUDs" (substance use disorders), responds to NIDA RFA-DA-70-012.  It brings together investigators with existing data that meet the requirements of the U01: Duke University (sample N-1400) and Virginia Commonwealth University (N-1000).  UNC...

Read more ...

Study 28 – Center on Antisocial Drug Dependence: the Genetics of HIV Risk Behavior

Investigators:  John Hewitt, Ph.D. (University of Colorado, Institute for Behavioral Genetics), Christian Hopfer, Ph.D. (University of Colorado Denver School of Medicine) Release Date:  TBA Abstract:  Component 1 of NIDA Center Grant 2P60DA011015 (Center PI: Hewitt, Comp1 PI: Hopfer) is conducting a genome wide association study (GWA) of adolescent substance abuse and dependence, conduct disorder, and HIV-related risk behaviors. Utilizing existing...

Read more ...

Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053

Investigator:  Kevin M. Gray, M.D. (Medical University of South Carolina) Release Date:  TBA Abstract:  This study is a 12-week, double-blind, randomized, placebo controlled trial of N-acetylcysteine (NAC) 1200mg twice daily, added to contingency management (CM), for the treatment of cannabis use among treatment-seeking cannabis-dependent adults (18-60).  Approximately 300 participants will be randomized into this 6-site study.  Participants will be asked...

Read more ...

Study 33 – Genome-wide Association Study of HIV-1 Host Genetics Among Injection Drug Users

Investigator:  Eric Johnson, Ph.D. (RTI International) Release Date: Available at dbGaP Abstract:  Vancouver Injection Drug User Study (VIDUS) The overaching goal of this project remains to identify and characterize genetic deteminants of HIV-1 susceptibility and resistance in a large sample of injection drug users (IDUs).  We plan to expand beyond our initial GWAS and replication of HIV acquisition and viral...

Read more ...

Study 34 – Attention Deficit-Hyperactivity Disorder (ADHD)

Investigators:  Robert K. Moyzis, Ph.D., Deborah L. Grady, Ph.D. (University of California, Irvine) Release Date:  TBA Abstract:  Project 1) Clinical Trials Probands and Families Cell line establishment funded by NIMH MH060660 (Robert Moyzis, PI) and DOE DE-FG03-97ER62485 (Robert Moyzis, PI), University of California, Irvine School of Medicine Molecular Genetic Epidemiology Study of ADHD/DRD4 (original 2000 abstract NIMH MH60660) Utilizing the...

Read more ...

Study 36 – Genetic Dissection in Pedigrees of Substance Use and Mood Disorders Comorbidity

Investigators: Henriette Raventós, Nelson B. Freimer, and Victor Reus Release Date: TBA Abstract: Substance use disorders (SUDs) and mood disorders (MDs) are highly prevalent disorders that, on their own, result in devastating outcomes and burden on individuals, their families, and society as a whole. Their comorbidity, however, complicates treatment and aggravates outcomes. While both types of disorders are heritable, the...

Read more ...

Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Investigator:  Madhukar Trivedi Release Date:  TBA (370 samples will be collected over the next 2 years) CTN-0068 Synopsis Study Objective: The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy of the...

Read more ...

Study 38 – Adolescent Brain Cognitive Development (ABCD) Study

UNDER CONSTRUCTION Investigator:  Release Date:  Data Available at NDA Files No instrument available

Read more ...

Study 42 – Genetics Analysis of Substance Use Disorder Using the Indiana Biobank Data

Investigators:  Dongbing Lai, Ph.D., Tae-Hwi Linus Schwantes-An, Ph.D., & Howard J. Edenberg, Ph.D. Release Date:  TBA Objective: The goal of this study is to identify genes related to substance use disorders, both individually (e.g. opioid, cannabis, cocaine, etc.) as well as those related to substance use disorders in general. The study participants were selected from the Indiana Biobank, which is...

Read more ...

Study 43 – Pediatric Imaging, Neurocognition, and Genetics (PING)

Investigators: Sarah Murray, Terry Jernigan Release Date: TBA Objective: This exciting new study has unique aims and unprecedented scope. The goal is to understand the genetic basis of individual differences in brain structure and connectivity, cognition, and personality. Since it is known that structural and functional connectivity in the brain undergoes continuous remodeling during childhood, the investigators will study 1400...

Read more ...